Advertisement
UK markets closed
  • FTSE 100

    8,285.71
    +99.36 (+1.21%)
     
  • FTSE 250

    21,356.30
    +471.95 (+2.26%)
     
  • AIM

    779.67
    +6.64 (+0.86%)
     
  • GBP/EUR

    1.1844
    -0.0006 (-0.05%)
     
  • GBP/USD

    1.2873
    +0.0019 (+0.14%)
     
  • Bitcoin GBP

    52,669.12
    +1,175.60 (+2.28%)
     
  • CMC Crypto 200

    1,372.01
    +41.41 (+3.11%)
     
  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     
  • DOW

    40,589.34
    +654.27 (+1.64%)
     
  • CRUDE OIL

    76.44
    -1.84 (-2.35%)
     
  • GOLD FUTURES

    2,385.70
    +32.20 (+1.37%)
     
  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     
  • HANG SENG

    17,021.31
    +16.34 (+0.10%)
     
  • DAX

    18,417.55
    +118.83 (+0.65%)
     
  • CAC 40

    7,517.68
    +90.66 (+1.22%)
     

Why Abbott Laboratories Stock Looks Ridiculously Overpriced

Why Abbott Laboratories Stock Looks Ridiculously Overpriced

Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. It benefited from COVID-related tests boosting its sales, but last year it ran into manufacturing issues that affected its baby formula production and hurt sales in its nutritional segment. The business is now getting back to normal, but the problem is that its valuation still needs to come down significantly before it's a worthwhile buy.